CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 1 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,404,920 | -58.8% | 476,634 | -40.0% | 0.12% | -59.3% |
| Q2 2023 | $25,270,475 | +69.5% | 794,919 | +30.0% | 0.30% | +47.8% |
| Q1 2023 | $14,911,217 | +1.8% | 611,366 | +31.6% | 0.20% | +3.6% |
| Q4 2022 | $14,647,428 | -3.4% | 464,408 | -13.4% | 0.20% | -7.5% |
| Q3 2022 | $15,158,000 | +124.4% | 536,385 | +109.9% | 0.21% | +103.8% |
| Q2 2022 | $6,756,000 | -46.7% | 255,533 | -29.4% | 0.10% | -49.5% |
| Q1 2022 | $12,665,000 | +64.6% | 361,753 | +52.4% | 0.21% | +87.3% |
| Q4 2021 | $7,694,000 | +33.5% | 237,326 | +21.5% | 0.11% | +17.0% |
| Q3 2021 | $5,762,000 | +56.5% | 195,331 | +35.9% | 0.09% | +36.2% |
| Q2 2021 | $3,682,000 | -31.8% | 143,712 | -63.4% | 0.07% | -42.5% |
| Q1 2021 | $5,395,000 | – | 392,910 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,713,470,000 | 41.39% |
| Perceptive Advisors | 6,511,727 | $184,021,000 | 5.34% |
| Finepoint Capital LP | 536,901 | $15,173,000 | 4.99% |
| Artal Group S.A. | 2,000,000 | $56,520,000 | 2.41% |
| Rock Springs Capital Management LP | 2,499,148 | $70,626,000 | 1.82% |
| Ikarian Capital, LLC | 178,100 | $5,033,000 | 1.00% |
| Hood River Capital Management LLC | 896,572 | $25,337,000 | 0.97% |
| Frazier Life Sciences Management, L.P. | 393,000 | $11,106,000 | 0.86% |
| HighVista Strategies LLC | 23,611 | $667,000 | 0.38% |
| FEDERATED HERMES, INC. | 3,313,333 | $93,635,000 | 0.27% |